Clinical Trial Detail

NCT ID NCT04285671
Title Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Necitumumab + Osimertinib + Trastuzumab

Age Groups: adult senior

No variant requirements are available.